Iranian
Biomedical Journal
Volume 28, Issue 1 (1-2024)
IBJ 2024, 28(1): 53-58 |
Back to browse issues page
Ethics code: sbmul.REC1394.112
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mehrzad N, Zamani M S, Rahimi A A, Shamaei M, Karimipoor M. Methylation Status of miR-34a and miR-126 in Non-Small Cell Lung Cancer (NSCLC) Tumor Tissues. IBJ 2024; 28 (1) :53-58
URL: http://ibj.pasteur.ac.ir/article-1-3845-en.html
URL: http://ibj.pasteur.ac.ir/article-1-3845-en.html
Abstract:
Background: MiR-34a and miR-126 mainly act as tumor suppressors and are often downregulated in various cancers, including non-small cell lung cancer (NSCLC). We aimed to determine the methylation status of miR-34a and miR-126 in NSCLC patients.
Methods: The current study included 63 paraffin-embedded NSCLC and paired adjacent normal tissues. After DNA extraction and bisulfite treatment, the methylation status of miR-34a and miR-126 were evaluated using the MSP method.
Results: There was no statistically significant difference between tumor and normal tissues regarding the methylation status of miR-34a and miR-126
(p > 0.05). Moreover, we found no significant correlation between the methylation status of miR-34a and miR-126 with patients’ demographic parameters, including gender, age, and pathology subtype (p > 0.05).
Conclusion: Considering the low expression of mir-126 and mir-34 in NSCLC, more sensitive methods are recommended to be exploited for detecting the level of methylation or underlying mechanisms other than promoter hypermethylation in silencing these genes in NSCLC.
Methods: The current study included 63 paraffin-embedded NSCLC and paired adjacent normal tissues. After DNA extraction and bisulfite treatment, the methylation status of miR-34a and miR-126 were evaluated using the MSP method.
Results: There was no statistically significant difference between tumor and normal tissues regarding the methylation status of miR-34a and miR-126
(p > 0.05). Moreover, we found no significant correlation between the methylation status of miR-34a and miR-126 with patients’ demographic parameters, including gender, age, and pathology subtype (p > 0.05).
Conclusion: Considering the low expression of mir-126 and mir-34 in NSCLC, more sensitive methods are recommended to be exploited for detecting the level of methylation or underlying mechanisms other than promoter hypermethylation in silencing these genes in NSCLC.
Type of Study: Short Communication |
Subject:
Molecular Genetics & Genomics
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. [DOI:10.3322/caac.21660]
2. Sussan TE, Pletcher MT, Murakami Y, Reeves RH. Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. Mol Cancer. 2005; 4:28. [DOI:10.1186/1476-4598-4-28]
3. Li ZH, Weng X, Xiong QY, Tu JH, Xiao A, Qiu W, et al. miR-34a expression in human breast cancer is associated with drug resistance. Oncotarget. 2017; 8(63):106270-82. [DOI:10.18632/oncotarget.22286]
4. Kalfert D, Ludvikova M, Pesta M, Ludvik J, Dostalova L, Kholová I. Multifunctional roles of miR-34a in cancer: a review with the emphasis on head and neck squamous cell carcinoma and thyroid cancer with clinical implications. Diagnostics(Basel). 2020; 10(8):563. [DOI:10.3390/diagnostics10080563]
5. Li X, Ren Z, Tang J. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014; 5(7):e1327. [DOI:10.1038/cddis.2014.270]
6. Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, Joshi P, et al. MiR-34a/c-dependent PDGFR-α/β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. Plos One. 2013; 8(6):e67581. [DOI:10.1371/journal.pone.0067581]
7. Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019; 38(1):53. [DOI:10.1186/s13046-019-1059-5]
8. Kwon H, Song K, Han C, Zhang J, Lu L, Chen W, et al. Epigenetic silencing of miRNA-34a in human cholangiocarcinoma via EZH2 and DNA methylation: impact on regulation of notch pathway. Am J Pathol. 2017; 187(10):2288-99. [DOI:10.1016/j.ajpath.2017.06.014]
9. Cohen Y, Merhavi Shoham E, Avraham RB, Frenkel S, Pe'er J, Goldenberg Cohen N. Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma. Exp Eye Res. 2008; 86(2):201-6. [DOI:10.1016/j.exer.2007.10.010]
10. Saito Y, Nakaoka T, Saito H. microRNA-34a as a therapeutic agent against human cancer. J Clin Med. 2015; 4(11):1951-9. [DOI:10.3390/jcm4111951]
11. Rouigari M, Dehbashi M, Ghaedi K, Pourhossein M. Targetome analysis revealed involvement of miR-126 in neurotrophin signaling pathway: a possible role in prevention of glioma development. Cell J. 2018; 20(2):150-6.
12. Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. Plos One. 2016; 11(4):e0153046. [DOI:10.1371/journal.pone.0153046]
13. Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 2013; 30(4):1976-84. [DOI:10.3892/or.2013.2633]
14. Zhang Z, Wang J, Cheng J, Yu X. Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells. Oncol Lett. 2018; 15(6):8412-6. [DOI:10.3892/ol.2018.8360]
15. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008; 105(40):15535-40. [DOI:10.1073/pnas.0808266105]
16. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013; 15(3):284-94. [DOI:10.1038/ncb2690]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |